Amgen (AMGN) Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 4 sell ratings, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings or view top-rated stocks.

13 brokerages have issued 12 month target prices for Amgen's shares. Their AMGN share price forecasts range from $182.00 to $290.00. On average, they predict the company's stock price to reach $250.94 in the next year. This suggests a possible upside of 13.7% from the stock's current price.
View analysts price targets for AMGN or view top-rated stocks among Wall Street analysts.

Amgen's stock was trading at $262.64 at the beginning of 2023. Since then, AMGN stock has decreased by 16.0% and is now trading at $220.65.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AMGN earnings forecast.

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings data on Thursday, April, 27th. The medical research company reported $3.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.84 by $0.14. The medical research company earned $6.11 billion during the quarter, compared to analyst estimates of $6.18 billion. Amgen had a trailing twelve-month return on equity of 248.47% and a net margin of 30.23%. Amgen's quarterly revenue was down 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $4.25 EPS.
Read the conference call transcript.

Amgen declared a quarterly dividend on Tuesday, March 7th. Shareholders of record on Thursday, May 18th will be given a dividend of $2.13 per share on Thursday, June 8th. This represents a $8.52 annualized dividend and a yield of 3.86%. The ex-dividend date is Wednesday, May 17th.
Read our dividend analysis for AMGN.

ETFs with the largest weight of Amgen (NASDAQ:AMGN) stock in their portfolio include VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), Timothy Plan Market Neutral ETF (TPMN), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Dynamic Pharmaceuticals ETF (PJP), Invesco Dynamic Biotechnology & Genome ETF (PBE) and Alpha Dog ETF (RUFF).

Amgen (NASDAQ:AMGN) pays an annual dividend of $8.52 per share and currently has a dividend yield of 3.93%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 57.92%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 44.24% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

Amgen updated its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $17.60-$18.70 for the period, compared to the consensus estimate of $17.72. The company issued revenue guidance of $26.20 billion-$27.30 billion, compared to the consensus revenue estimate of $26.70 billion.

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.13%), State Street Corp (5.46%), Geode Capital Management LLC (2.14%), Charles Schwab Investment Management Inc. (2.01%), Bank of New York Mellon Corp (1.01%) and FMR LLC (0.99%). Insiders that own company stock include Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Robert Eckert, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends.

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMGN stock can currently be purchased for approximately $220.65.

Amgen (NASDAQ:AMGN) has a market capitalization of $117.90 billion and generates $26.32 billion in revenue each year. The medical research company earns $6.55 billion in net income (profit) each year or $14.71 on an earnings per share basis.

The company employs 25,200 workers across the globe.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.